The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women

Fertility and Sterility

Volumn 88, Issue 2, 2007, Pages 530-532

  Zeyneloglu, Hulusi B ^a   Oktem, Mesut ^a   Haberal, Nihan A ^a   Esinler, Ibrahim ^a   Kuscu, Esra ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CAL D VITA; CALCIUM; RALOXIFENE; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; CYTOLOGY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MATURATION; PH; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SYMPTOM; VAGINA SMEAR; VAGINAL MATURATION INDEX;

BONE DENSITY CONSERVATION AGENTS; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FEMALE UROGENITAL DISEASES; HEALTH STATUS INDICATORS; HUMANS; HYDROGEN-ION CONCENTRATION; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; VAGINA; VAGINAL SMEARS; VITAMIN D;

EID: 34547655607     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.11.112     Document Type: Article

References (13)

1. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 (1997) 1641-1647
2. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
3. Cohen F.J., Watts S., Shah A., Akers R., and Plouffe Jr. L. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 95 (2000) 104-110
4. Davies G.C., Huster W.J., Lu Y., Plouffe Jr. L., and Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 93 (1999) 558-565
5. Parsons A., Merritt D., Rosen A., Heath III H., Siddhanti S., and Plouffe Jr. L. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 101 (2003) 346-352
6. Yildirim B., Kaleli B., Duzcan E., and Topuz O. The effects of postmenopausal Vitamin D treatment on vaginal atrophy. Maturitas 49 (2004) 334-337
7. Hammond D.O. Cytological assessment of climacteric patients. Clin Obstet Gynaecol 4 (1977) 49-70
8. Hustin J., and Van den Eynde J.P. Cytologic evaluation of the effect of various estrogens given in postmenopause. Acta Cytol 21 (1977) 225-228
9. Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 102 (2003) 823-834
10. Vardy M.D., Lindsay R., Scotti R.J., Mikhail M., Richart R.M., Nieves J., et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol 189 (2003) 81-88
11. Checa M.A., Garrido A., Prat M., Conangla M., Rueda C., and Carreras R. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study. Maturitas 52 (2005) 70-77
12. Komi J., Lankinen K.S., Harkonen P., Degregorio M.W., Voipio S., Kivinen S., et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 12 (2005) 202-209
13. Kessel B., Nachtigall L., Plouffe L., Siddhanti S., Rosen A., and Parsons A. Effect of raloxifene on sexual function in postmenopausal women. Climacteric 6 (2003) 248-256